

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTAS PHARMACEUTICALS LTD.,
Petitioner,

v.

ATOSSA THERAPEUTICS, INC.,
Patent Owner

Case PGR2025-00043
Patent 12,071,391

**PETITIONER'S AND PATENT OWNER'S JOINT MOTION TO
TERMINATE PURSUANT TO 35 U.S.C. § 327**

I. STATEMENT OF RELIEF REQUESTED

Pursuant to 35 U.S.C. § 327(a) and 37 C.F.R. § 42.72, Petitioner Intas Pharmaceuticals Ltd. (“Intas”) and Patent Owner Atossa Therapeutics, Inc. (“Atossa”) jointly request termination of Intas from PGR2025-00043 concerning U.S. Patent No. 12,071,391 (“the ’391 patent”). In addition, the parties request that this proceeding be terminated in its entirety.

Intas and Atossa notified the Board of their settlement on April 13, 2026, and received authorization to file this joint motion to terminate on April 22, 2026.

II. STATEMENT OF FACTS

In support of the Motion to Terminate Proceeding, Intas and Atossa state as follows:

Intas filed a petition for post-grant review on April 3, 2025, and Atossa filed a request for discretionary denial on July 7, 2025, and a preliminary response on August 5, 2025. On August 29, 2025, the petition was referred to the Board and on November 3, 2025, the Board instituted this post-grant review. Pap. 12; Pap. 13.

Intas and Atossa have settled their dispute relating to the ’391 patent and related patents, and have agreed to move to terminate this post-grant review.

The parties’ Settlement Agreement has been made in writing, and a true and correct copy will be concurrently filed with this Office as business confidential information pursuant to 35 U.S.C. § 327(b) as Exhibit 1039. There are no collateral

agreements. Because the Settlement Agreement is confidential, Petitioner and Patent Owner respectfully request that it be treated as business confidential information, be kept separate from the underlying patent file, and be made available only as provided in 35 U.S.C. § 327(b) and 37 C.F.R. § 42.74(c), and have filed herewith a separate paper setting forth this request.

III. RELATED LITIGATION

There are no pending district court litigations involving the '391 patent. There are no other PTAB proceedings involving the '391 patent.

IV. ARGUMENT

The statutory provision on a settlement relating to post-grant review provides that a post-grant review “shall be terminated with respect to any petitioner upon the joint request of the petitioner and the patent owner, unless the Office has decided the merits of the proceeding before the request for termination is filed.” 35 U.S.C. § 327(a). Because the Board has not decided the merits of this proceeding, and because Intas and Atossa have jointly requested termination, the Board should terminate Intas under § 327(a).

Intas and Atossa request that this proceeding be terminated in its entirety. Section 327(a) further provides that, “[i]f no petitioner remains in the post-grant review, the Office may terminate the review or proceed to final written decision under section 328(a).” *Id.* This proceeding was recently instituted, and termination

would save additional expenditure or resources by the Board, as well as by the parties, and would further the purpose of post-grant proceedings to provide an efficient and less costly alternative forum for patent disputes (including by encouraging settlement). The Board has routinely terminated proceedings at the request of settling parties in cases that have progressed much further than the present proceeding. See, e.g., *Ascend Performance Materials Operations LLC v. Samsung SDI Co., LTD*, IPR2020-00349, Pap. 64, 2-5 (Mar. 3, 2022) (granting motion to terminate filed after issuance of final written decision and prior to the issuance of a new final written decision on remand from the Director); *Taiwan Semiconductor Mfg. Co. Ltd. v. Godo Kaisha IP Bridge 1*, IPR2017-01862, Pap. 39 (Jan. 24, 2019) (granting termination of proceeding in view of settlement two months after oral argument); *Petroleum Geo-Services Inc. v. WesternGeco LLC*, IPR2016-00407, Pap. 29 at 2, 3-4 (July 5, 2017) (terminating proceeding where parties notified the Board of settlement less than a week before the statutory deadline for a final written decision); *Lam Research Corp. v. Flamm*, IPR2015-01764, Pap. 27, 4, 6 (Dec. 15, 2016) (granting full termination of proceeding after oral argument despite “extremely advanced nature” of proceeding, when “substantial resources—both on the part of the Board, as well as the parties—have been invested in this matter”); *Volusion, Inc. v. Versata Software, Inc.*, CBM2013-00018, Pap. 52, 2-3 (June 17,

2014) (granting motion to terminate instituted proceeding in its entirety after final oral hearing).

Indeed, the Board has stated an *expectation* that proceedings such as this will be terminated after the filing of a settlement agreement: “There are strong public policy reasons to favor settlement between the parties to a proceeding. . . . The Board *expects that a proceeding will terminate after the filing of a settlement agreement*, unless the Board has already decided the merits of the proceeding.” Patent Trial and Appeal Board, Consolidated Trial Practice Guide, at 86 (Nov. 2019) (emphasis added).

For at least the reasons noted above, the Board's expectation that such proceedings should be terminated is proper and well justified here.

V. CONCLUSION

For the foregoing reasons, Intas and Atossa respectfully request that the Board terminate Intas, and grant this joint motion to terminate PGR2025-00043 in its entirety.

Dated: April 23, 2026

/Alejandro Menchaca/
Alejandro Menchaca
Reg. No. 34,389
McAndrews, Held & Malloy, Ltd.
500 West Madison Street, 34th Floor
Chicago, IL 60661

Respectfully submitted by:

/Megan Raymond/
Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
801 17th Street NW, Suite 1050
Washington, DC 20006

Petitioner's and Patent Owner's Joint Motion to Terminate Pursuant to 35 U.S.C. § 327

Telephone: (312) 775-8103
amenchaca@mcandrews-ip.com

P: (202) 505-5878
megan.raymond@groombridgewu.com

Ben J. Mahon
Reg. No. 78,178
McAndrews, Held & Malloy, Ltd.
500 West Madison Street, 34th Floor
Chicago, IL 60661
Telephone: (312) 775-8093
bmahon@mcandrews-ip.com

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
801 17th Street NW, Suite 1050
Washington, DC 20006
P: (202) 505-5832
steve.baughman@groombridgewu.com

*Attorneys For Petitioner Intas
Pharmaceuticals Ltd.*

Michael Milea (Reg. No. 71,863)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
565 5th Avenue, Suite 2900
New York, NY 10017
P: (332) 269-0029
mike.milea@groombridgewu.com

Han Xu (*pro hac vice*)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
2F Marunouchi Nijubashi Bldg, 3-2-2
Marunouchi
Chiyoda-ku, Tokyo 100-0005 Japan
han.xu@groombridgewu.com

Jacob Berman (*pro hac vice*)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
565 5th Avenue, Suite 2900
New York, NY 10017
P: (332) 269-1106
jacob.berman@groombridgewu.com

Hayley R. LeBlanc (*pro hac vice*)
GROOMBRIDGE, WU, BAUGHMAN &
STONE LLP
801 17th Street NW, Suite 1050
Washington, DC 20006

Petitioner's and Patent Owner's Joint Motion to Terminate Pursuant to 35 U.S.C. § 327

P: (202) 871-9019
hayley.leblanc@groombridgewu.com

*Attorneys For Patent Owner Atossa,
Therapeutics, Inc.*

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of PETITIONER'S AND PATENT OWNER'S JOINT MOTION TO TERMINATE PURSUANT TO 35 U.S.C. § 327 has been served in its entirety by causing the aforementioned document to be electronically mailed to the following attorneys of record for the Patent Owner listed below:

Megan Raymond
megan.raymond@groombridgewu.com

J. Steven Baughman
steve.baughman@groombridgewu.com

Atossa-Intas@groombridgewu.com

Dated: April 23, 2026

Respectfully submitted,

By: /Alejandro Menchaca/
Alejandro Menchaca